We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

It was developed with Sanofi (NASDAQ: SNY), who actually claims the revenues and splits profits with Regeneron. Regeneron ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Days after the U.S. FDA cancelled an annual meeting to discuss the makeup of the following season's flu vaccine, FDA ...

FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850 million floating rate notes, due March 2027, bearing interest at ...